Sometimes a stock just needs a little good news. For Onconetix, Inc. (ONCO), that news came in the form of an acquisition update and a reverse stock split, sending shares soaring 71% in Friday's premarket session.

Here's what's happening: On Wednesday, the company provided a significant update on its pending acquisition of Realbotix. While the financial terms remain undisclosed, the deal is expected to boost Onconetix's capabilities in the fast-moving world of AI and robotics.

Realbotix recently made waves by showcasing its humanoid robot in a live trial at Ericsson's U.S. headquarters. The demo highlighted what the company calls an "AI-agnostic" architecture, which essentially means its robots can play nice with various AI systems and cloud platforms. That kind of flexibility could make Realbotix a key player in enterprise robotics, which is presumably why Onconetix is so keen to bring it into the fold.

In a separate but related move, Onconetix also announced a 1-for-5 reverse stock split this week, set to take effect on March 25. A reverse split reduces the number of shares outstanding and increases the price per share. Companies often do this to meet exchange listing requirements or to make the stock appear more substantial to investors, though it doesn't change the company's underlying market value.

Now, let's talk about the stock's wild ride. A 71% premarket pop is nothing to sneeze at, but it's important to look at the bigger picture. According to the technical data, the stock is currently trading 76% above its 20-day simple moving average, which shows serious short-term momentum. It's also 4.7% above its 50-day average.

But the longer-term view tells a different story. The stock remains 36.3% below its 100-day moving average and a whopping 60.5% below its 200-day average. Over the past 12 months, shares have plummeted nearly 93%, and they're still hovering much closer to their 52-week low of $2.19 than to any highs.

So, what's an investor to make of this? You've got a stock that's getting a massive short-term boost from some corporate news, but it's coming off a brutal year. The Realbotix acquisition could be a genuine growth catalyst if the robotics play pans out. The reverse split might clean up the share structure. But one day of huge gains doesn't erase a year of pain. As of premarket trading Friday, Onconetix shares were at $5.53. It's a dramatic move, but the real test will be whether the company can turn this momentum into a sustained recovery.